Search

To investigate the association between the 3 most frequently observed single nucleotide polymorphisms of the NAT2 gene and the risk of developing prostate cancer in the Turkish population. Materials and methods: A total of 110 unrelated patients with prostate cancer were included in this case-control association study and constituted the study group. The control group also consisted of 150 unrelated but healthy men. Genomic DNA was isolated from peripheral blood leukocytes of all patients and analyzed with a sensitive real-time PCR method. After melting curve analysis genotypes were identified for the NAT2*5A, NAT2*6A, and NAT2*7A/B polymorphisms. Results: Prostate cancer patients had a higher frequency of the mutant NAT2*6A (13.6% versus 4.0%, P = 0.009) and heterozygote NAT2*7A/B (20.9% versus 9.3%, P = 0.008) genotypes when compared with the controls. Conclusion: The NAT2*6A and NAT2*7A/B gene polymorphisms were significantly associated with prostate cancer in the Turkish population. Real-time PCR analysis of the NAT2 acetylator phenotype can therefore be used to recognize individuals with a high risk of developing prostate cancer.